Detail akcie ALX Oncology Rg online

Business Summary: ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ALX Oncology Holdings Inc revenues was not reported. Net loss decreased 25% to $78.8M. Lower net loss reflects Reserach and developement decrease of 33% to $40.5M (expense), Stock-based Compensation in R&D decrease of 66% to $4.9M (expense), Labor & Related Expenses in R&D decrease of 21% to $13.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.05 to -$1.48.